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Abstract
Objectives: To compare the efficacy and safety of an individualized treatment-simplification strategy consisting of switching
from a highly-active anti-retroviral treatment (HAART) with a ritonavir-boosted protease inhibitor (PI/r) and 2 nucleoside
reverse-transcriptase inhibitors (NRTIs) to lopinavir/ritonavir (LPV/r) monotherapy, with intensification by 2 NRTIs if
necessary, to that of continuing their HAART.
Methods: This is a one-year, randomized, open-label, multi-center study in virologically-suppressed HIV-1-infected adults on
their first PI/r-containing treatment, randomized to either LPV/r-monotherapy or continue their current treatment.
Treatment efficacy was determined by plasma HIV-1 RNA viral load (VL), time-to-virologic rebound, patient-reported
outcomes (PROs) and CD4+T-cell-count changes. Safety was assessed with the incidence of treatment-emergent adverse
events (AE).
Results: Forty-one patients were randomized to LPV/r and 39 to continue their HAART. No statistically-significant differences
between the two study groups in demographics and baseline characteristics were observed. At day-360, 71(39:LPV/
r;32:HAART) patients completed treatment, while 9(2:LPV/r;7:HAART) discontinued. In a Last Observation Carried Forward
Intent-to-Treat analysis, 40(98%) patients on LPV/r and 37(95%) on HAART had VL,200copies/mL (P=0.61). Time-to-
virologic rebound, changes in PROs, CD4+ T-cell-count and VL from baseline, also exhibited no statistically-significant
between-group differences. Most frequent AEs were diarrhea (19%), headache (18%) and influenza (16%). Four (10%)
patients on LPV/r were intensified with 2 NRTIs, all regaining virologic control. Eight serious AEs were reported by 5(2:LPV/
r;3:HAART) patients.
Conclusion: At day-360, virologic efficacy and safety of LPV/r appears comparable to that of a PI+2NRTIs HAART. These
results suggest that our individualized, simplified maintenance strategy with LPV/r-monotherapy and protocol-mandated
NRTI re-introduction upon viral rebound, in virologically-suppressed patients merits further prospective long-term
evaluation.
Trial Registration: ClinicalTrials.gov NCT00159224
Citation: Cahn P, Montaner J, Junod P, Patterson P, Krolewiecki A, et al. (2011) Pilot, Randomized Study Assessing Safety, Tolerability and Efficacy of Simplified
LPV/r Maintenance Therapy in HIV Patients on the 1
st PI-Based Regimen. PLoS ONE 6(8): e23726. doi:10.1371/journal.pone.0023726
Editor: Alan Landay, Rush University, United States of America
Received January 31, 2011; Accepted July 25, 2011; Published August 19, 2011
Copyright:  2011 Cahn et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by a grant-in-aid by Abbott Canada. The funder was involved in the conception and design of the experiment but had no
role in data collection and analysis, decision to publish, or writing of the manuscript. JSS Medical Research, a CRO contracted by Abbott, analyzed the data and
wrote the manuscript.
Competing Interests: NA is an Abbott employee, NL, ER and JSS are employees of JSS Medical Research, the CRO contracted by Abbott to conduct the study
and perform the data analysis. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: jsampalis@jssresearch.com
Introduction
The standard treatment approach in HIV-1 infection involves
using a combination of at least three antiretroviral (ARV) drugs,
designated highly active antiretroviral therapy (HAART) to fully
suppress plasma HIV-1 RNA viral load (VL), in a sustainable
fashion. Currently recommended first line antiretroviral regimens
consist of two nucleoside (NRTI) or nucleotide (NtRTI) analog
reverse transcriptase inhibitors and either a non-nucleoside reverse
transcriptase inhibitor (NNRTI), an integrase strand transfer
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23726inhibitor (INSTI) or a ritonavir-boosted protease inhibitor (PI/r)
[1]. While adherence to HAART regimens is essential to achieve
and maintain long-term virological suppression [2,3,4,5], subop-
timal adherence is often observed due to the complexity of the
treatment regimens as well as their associated short- and long-term
toxicities. The subsequent failure to adequately suppress viral
replication permits the rapid selection of resistant mutations, viral
rebound and resumption of disease progression [6,7].
A number of regimen simplification treatment approaches have
been explored to improve adherence, reduce the risk of virologic
failure and long-term toxicities, and enhance the patient’s quality
of life [8]. In induction/maintenance therapy, a standard three
drug regimen is used to achieve virologic suppression, followed by
the use of a simpler regimen to maintain viral control. Lopinavir
(LPV) is a PI with potent in vitro activity against HIV [9] which has
been clinically used in combination with ritonavir (r), a
cytochrome P450 3A4 enzyme inhibitor, to enhance its pharma-
cokinetic properties. LPV/r-based combination ARV regimens
have been shown to be effective in the treatment of ARV therapy
(ART)-naive patients, both short-term and long-term [4,10,11].
However, when used as monotherapy LPV/r was found to achieve
lower levels of virologic suppression as compared to LPV/r-based
triple ART [12]. In contrast, in a more recent study, Arribas et al.
demonstrated that maintenance LPV/r monotherapy was not
inferior to triple therapy (LPV/r + 2 NRTIs) in its ability to
maintain suppression of the VL among patients with prior stable
virologic suppression [13].
The objective of this pilot study was to assess the efficacy and
safety of a simplified strategy aimed to optimize the use of LPV/r
monotherapy maintenance, whereby intensification with two
NRTIs was allowed if VL in plasma became detectable, among
patients stably suppressed on PI/r triple-combination therapy.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Patients
Eligible patients were HIV-1 infected adults who: i) were on
their first ART regimen, composed of any two NRTIs plus LPV/r
or a PI/r combination; and ii) had been virologically suppressed
with a HIV-1 RNA viral load of ,50 copies/ml for at least 6
months prior to study entry and a CD4+ T-cell count $100 cells/
mm
3. Patients were excluded if they were HBsAg+, had active
tuberculosis or an opportunistic infection, active malignancy
(except Kaposi’s Sarcoma), elevated hepatic transaminases
(ALT/AST .5x Upper Limit of Normal), or an uncontrolled
substance abuse or psychiatric illness that could preclude
compliance with the protocol. Patients were also excluded if they
were pregnant or lactating, had received an investigational drug
within 30 days prior to study initiation, or had modified their ART
within three months of study entry or were intending to do so
during the course of the study.
Study Design
This was a one-year pilot, prospective, open-label, randomized,
comparative, multi-center study. The study was conducted
according to the tenets of the Declaration of Helsinki and
approved by an independent ethics review board (Ethica Clinical
Research Inc., Montreal, Quebec). All participating patients
provided written informed consent prior to study entry. Patients
were recruited between January 2005 and July 2007 across 9 sites
in Canada, Argentina, and Mexico, and were randomized to
receive in a 1:1 ratio either monotherapy with LPV/r (IM) or the
standard HAART regimen (ST). Randomization was centrally
coordinated by a third-party data management center and was
stratified by center. A sealed envelope containing the randomized
allocation was sent by the data management center to the
physician who was blinded for the randomization schedule, and
was opened by the patient. The allocation document was
subsequently signed by the physician and mailed back to the data
management center. Patients randomized to the IM group were
provided with co-formulated LPV/r 133.3/33.3 mg soft gel
capsules and were instructed to take 3 capsules BID orally with
food. Clinical assessments took place at Screening/Baseline (Day -
1) and Days 15, 30, 60, 90, 120, 150, 180, 240, 300, and 360.
Efficacy measures included plasma HIV-1 RNA levels and CD4+
T-cell counts. Safety was assessed with the incidence of treatment
emergent adverse events (AE), vital signs, clinical laboratory data,
including venous lactic acid and serum lipid levels.
Patients with HIV-1 RNA .50 copies/ml in one visit were
retested between 7 and 30 days later. If the second viral load was
,50 copies/ml the patients continued on their randomized
therapy, while if it was .50 and ,200 copies/mL the patients
were followed on protocol and were retested until either ,50 or
.200 copies/ml was confirmed. If the second viral load was
.200 copies/ml, patients in the ST arm were considered to have
met the endpoint of virologic failure, and treatment was to be
modified at the discretion of the investigator/treating physician. In
the monotherapy arm, if the second viral load was .200 copies/
ml, intensification with two NRTIs was allowed (either the same
NRTIs as before randomization or different ones) and the patient
was maintained on the randomized treatment starting the visit
schedule from the beginning. Intensified patients who developed a
viral load of .50 copies/ml and a subsequent viral load of
.200 copies/ml were considered to have reached the study
endpoint of virologic failure, and therapy was to be modified at the
discretion of the investigator or the treating physician.
Outcome Measures
The primary efficacy endpoint was the percentage of patients
with plasma HIV-1 RNA level ,200 copies/ml at Day 360.
Secondary efficacy measures were the percentage of patients with
plasma HIV-1 RNA ,50 copies/mL at Day 360 (as determined
by the Roche AMPLICOR HIV-1 MONITOR Ultra-Sensitive
Assay, version 1.5; lower limit of detection (LLOD) =50 copies/
mL), the time to confirmed virologic rebound ($200 copies/ml
and $50 copies/ml) or meeting the criteria for virologic failure as
described above through Day 360, as well as the mean change in
Viral Load and CD4+ T-cell count from baseline to final
assessment.
The impact on patient-reported outcomes (PROs) was assessed
using the Symptoms Distress Module (SDM) which was admin-
istered at each visit. This questionnaire was developed by the
NIAID AIDS Clinical Trials group and consists of 20 questions
evaluating the impact of specific symptoms, possibly related to the
treatment, on the patient’s life. The total score is calculated as the
sum of the five point response to the 20 questions where 0=
symptom not reported, 1= I have this symptom and it doesn’t
bother me, 2= I have this symptom and it bothers me a little, 3=
I have this symptom and it bothers me, and 4= I have this
symptom and it bothers me a lot. The SDM score ranges from 0 to
80 and higher values indicate worse PROs.
Safety was determined by the incidence of treatment emergent
adverse events (AE), changes in vital signs and clinical laboratory
data, as well as the occurrence of metabolic toxicity as indicated by
Simplified LPV/r Maintenance Strategy in HIV-1
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relationship to the study medication was based on the judgment
of the treating physician.
Statistical Methods
Sample size calculations for the current study were based on the
expected difference between the two treatment groups in the
proportion of patients with virologic control defined as ,200 cop-
ies/mL at Day 360. Previous studies have shown that at 48 weeks,
approximately 90% of virologically suppressed patients treated
with LPV/r remain virologically controlled [14]. In order to detect
as statistically significant a relative risk for being virologically
suppressed of 1.35 with 80% power and two tailed significance
level of 5%, a total of 50 fully evaluable patients per group were
required. The study was ended when 80 patients were enrolled
due to low recruitment rate.
Between-group differences in the rates of virologic control
(proportion of patients with viral load ,200 copies/mL and
,50 copies/mL at day 360) were assessed with the Chi-Square
test. The odds ratio (OR) with 95% confidence intervals was used
as the measure of treatment effect. In this analysis the Last
Observation Carried Forward (LOCF) approach was used for
patients that discontinued the study prior to the 360 day follow up.
The time to first confirmed virologic rebound was estimated using
the Kaplan Meier Survival function, and the maximum likelihood
test was used to compare the two groups with respect to the rate of
virologic rebound. The Student’s t-test for independent samples
was used to assess between group differences with respect to the
change in CD4+ T-cell count, VL and SDM score from baseline
to final assessment. Repeated Measures Analysis of variance with
Mixed Effects to account for unequal follow up were used to assess
the treatment effect on CD4+ T-cell count, VL and SDM over
time. Paired Student’s t-test was used to descriptively assess the
change in CD4+ T-cell count, VL and SDM within the two
treatment groups, while simple linear regression models were used
to assess these changes over time within the two treatment groups.
Safety was assessed by the incidence of adverse events. All analyses
were performed using the intent-to-treat population, defined as all
patients enrolled who had taken at least one dose of the study
medications and had completed at least one follow up visit.
Results
A total of 80 patients were enrolled in the study, met the intent-
to-treat (ITT) criteria and were randomly assigned to treatment, of
which, 71 (89%) completed the study and 9 (11%) prematurely
discontinued. Among these 9 discontinued patients, 7 belonged to
the ST group and 2 to the IM group. Reasons for discontinuation
and patient disposition are described in Figure 1.
As summarized in Table 1, demographics and baseline
characteristics for the ITT population exhibited no statistically
significant differences between groups. The mean (SD) age at
screening was 39 (9.3) years. Patients were predominantly males
(84%) and Caucasian (94%), with a mean (SD) duration since
initial HIV diagnosis of 3.3 (3.0) years. At baseline, the mean (SD)
CD4+ T-cell count and log10 HIV-1 RNA were 383 (195) cells/
mm
3 and 1.68 (0.08) log10copies/ml, respectively. The most
common ARV medications used prior to randomization, were:
lamivudine 44 (55%), LPV/r 44 (55%), low dose ritonavir 34
(42%), zidovudine/lamivudine 31 (39%), and zidovudine 26
(33%). There were 23 patients on a LPV/r combination and 18
patients on a non-LPV/r regimen in the IM group, prior to
randomization. Similarly, 23 patients in the ST group were on a
LPV/r combination while 16 patients were on a non-LPV/r
combination.
The primary outcome measure of the study was the proportion
of patients with plasma HIV-1 RNA ,200 copies/ml at 360 days.
In an ITT analysis using the LOCF principle, 37 of the 39 patients
(95%) in the ST group and 40 of the 41 patients (98%) in the IM
group had plasma HIV-1 RNA ,200 copies/ml (OR=0.46; 95%
CI: 0.04–5.31; P=0.611). With respect to the proportion of
Table 1. Patient Demographics and Baseline Characteristics
in the ITT population.
Parameter:
ST
(N=39)
IM
(N=41)
Total
(N=80)
Age (years)
Mean (SD) 37.7 (8.51) 39.9 (9.89) 38.9 (9.25)
Median (Range) 37.0
(24.0 – 59.0)
39.0
(23.0 – 75.0)
38.0
(23.0 – 75.0)
Gender
Male; N (%) 36 (92.3%) 31 (75.6%) 67 (83.8%)
Race: N (%)
Caucasian 36 (92.3%) 39 (95.1%) 75 (93.8%)
American Indian/
Alaska Native
3 (7.7%) 2 (4.9%) 5 (6.2%)
Disease duration
2(years)
N2 6 2 7 5 3
Mean (SD) 3.4 (3.85) 3.1 (2.00) 3.3 (3.02)
Absolute CD4+ T-cell
count (cell/mm
3)
N3 9 4 1 8 0
Mean (SD) 401.2
(222.5)
364.6
(164.3)
382.5
(194.5)
Viral load (log10 RNA
copies/mL)
N3 9 4 1 8 0
Mean (SD) 1.689 (0.063) 1.680 (0.087) 1.684 (0.076)
doi:10.1371/journal.pone.0023726.t001
Figure 1. Patient Disposition. * ST: Standard Treatment; IM:
Induction/Maintenance.
doi:10.1371/journal.pone.0023726.g001
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* Censored observations represent patients who exited the study without experiencing virologic rebound.
doi:10.1371/journal.pone.0023726.g002
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applying again the LOCF principle, there were 36 patients (92%)
for the ST and 39 (95%) for the IM group (OR=0.61; 95% CI:
0.097–3.897; P=0.671). Four (10%) patients on LPV/r were
intensified with 2 NRTIs and all of them regained virologic
control, as demonstrated by achieving a plasma HIV-1 RNA
,50 copies/mL following the intensification.
The Kaplan Meier estimates of the proportion of patients with
sustained virologic response are shown in Figure 2. Applying the
maximum likelihood analysis on these estimates for the time to first
confirmed virologic rebound of $200 plasma HIV-1 RNA copies/
ml, a hazard ratio (95% CI) of 2.62 (0.26–24.20) for IM versus ST
was calculated, which was not statistically significant (P=0.405)
(Figure 2a). Similarly, the time to first confirmed virologic rebound
of $50 HIV-1 RNA copies/ml was comparable in the two groups
with an estimated hazard ratio (95% CI) of 4.19 (0.90–19.43),
which only approached statistical significance (P=0.067)
(Figure 2b).
The results in Table 2 show that there were no significant
between-group differences with respect to the mean changes in
CD4+ T-cell counts (P=0.463) and HIV-1 VL (P=0.361) from
baseline to final assessment. Furthermore, Repeated Measures
Analysis of Variance with Mixed Effects indicate that the change
in these parameters over time during the 360 day follow up period,
was also similar between the two groups (P=0.794 and P=0.413,
respectively).
Using the SDM to assess the PROs, it was determined that the
patients in the IM group experienced a decline in the SDM from
31.7 at baseline to 26.2 at 360 days (P=0.003), indicating a
statistically significant improvement in the PROs. On the
contrary, patients in the ST group experienced a statistically
non-significant decline from 31.8 at baseline to 29.6 at 360 days
(P=0.094). Nevertheless, the difference in the change in SDM
from baseline to 360 days of treatment between the two treatment
groups was not statistically significant (P=0.131). Similarly, linear
regression analysis showed that the change in SDM over time was
statistically significant for the IM group (P=0.001), but not for the
ST group (P=0.949) (Figure 3). However, Repeated Measures
Analysis of Variance again failed to detect a significant between-
group difference with respect to the change in SDM over time
(P=0.189).
A total of 658 AEs were reported for 66 (83%) patients. Of
these, 269 AEs were reported by 32 (82%) patients in the ST
group while 389 AEs were reported by 34 (83%) patients in the IM
group. Both the incidence and the profile of adverse events were
comparable between the two groups, showing no apparent
differences. The most frequently reported adverse events were
diarrhea (19%), headache (18%), influenza (16%), nasopharyngitis
(13%), back pain (10%), hypertriglyceremia (8%) and insomnia
(8%). Adverse events were predominantly mild in severity and
judged unrelated to the study drug. There were three SAEs
reported by two patients in the IM group (1 thrombocytopenia, 1
upper abdominal pain and 1 pneumonia) and five SAEs reported
by three patients in the ST group, of which seven were considered
severe and one in the IM group was moderate. All SAEs were
considered unrelated to the study drug.
Discussion
The goal of this pilot, randomized clinical trial was to compare
an individualized, simplified maintenance LPV/r-based strategy
with reintroduction of two NRTIs upon viral rebound in plasma,
to the standard continued triple-drug therapy with respect to
sustained virologic response over 360 days, among virologically
suppressed HIV-1-infected patients on their first PI/r-based
HAART regimen. Our results demonstrate comparable safety,
efficacy and tolerability for the induction/maintenance strategy
and the continued standard HAART treatment. Overall, virologic
success rates of over 90% and 95% were documented when using
the 50 and 200 copies/mL plasma viral load thresholds,
respectively. Importantly, intensification by NRTIs was required
in only 10% of the patients randomized to LPV/r which, in all
instances, resulted in regaining virologic control as defined by a
sustained plasma HIV-1 RNA level of ,50 copies/mL. Additional
immunologic and virologic parameters including the change in the
CD4-T-cell count and the viral load from baseline to final
assessment, the rate of change in these two parameters over the
360 days, and time to virologic rebound defined as .200 HIV-1
RNA copies/ml, were also not statistically different between the
two groups. With regards to the time to VL.50 HIV-1 RNA
copies/ml, a trend towards the favor of the ST was observed,
which was however not statistically significant. Previous studies
have shown that ritonavir-boosted PI monotherapy is associated
with low-level viremia (50–200 copies/mL), the clinical relevance
of which is still not clear [15]. Changes in PROs, as measured by
the SDM, favored the induction/maintenance group showing
bigger improvement in the patients randomized to the simplified
maintenance strategy.
The results of the current study are in agreement with those
from the OK04 study [13,14], showing that 85% vs. 90% and
77% vs. 78% of patients on LPV/r monotherapy vs. patients on
standard triple therapy group remained virologically suppressed
Table 2. Virologic and Immunologic Response.
Parameter Visit ST IM Total P - Value
1
N Mean (SD) N Mean (SD) N Mean (SD)
Absolute CD4+ T-cell
count
Baseline 39 401.2 (222.5) 41 364.6 (164.3) 80 382.5 (194.5) 0.404
360 days 32 478.6 (246.4) 39 453.8 (249.4) 71 465.0 (246.6) 0.678
Change 32 56.8 (168.93) 39 89.3 (196.18) 71 74.6 (183.84) 0.463
Viral load log10 RNA
copies/ml
Baseline 39 1.689 (0.063) 41 1.680 (0.087) 80 1.684 (0.076) 0.592
360 days 31 1.692 (0.079) 39 1.734 (0.249) 70 1.715 (0.193) 0.369
Change 31 0.006 (0.032) 39 0.055 (0.245) 70 0.033 (0.184) 0.361
1Based on student’s t-test for independent samples.
doi:10.1371/journal.pone.0023726.t002
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respectively. Furthermore, the longer studies by Pulido et al. [16],
Cameron et al. [17] and Nunes et al. [18] also demonstrated
comparable virological suppression defined as ,50 copies/ml and
,80 copies/ml, respectively, between the LPV/r monotherapy
and combination therapy arms at 48 months and at later stages.
Use of class-sparing regimens, such as the one described in this
study, offers the advantage of saving alternative ARV classes as a
‘‘back-up’’ option for new ARV combinations, in the case of ART
failure. Furthermore, such regimens could help avoid the side
effects associated with nucleoside analogue-containing regimens
including renal or bone toxicity and high cardiovascular risk
associated with tenofovir disoproxil fumarate and abacavir,
respectively [19,20,21]. Mitochondrial toxicity with older NRTIs,
currently used in resource-limited settings, was described by
Brinkman and coworkers [22], and confirmed by other authors
[23,24]. The clinical presentation of NRTI toxicities seen in HIV-
infected individuals is dependent on the organ system affected,
including lipoatrophy, lactic acidosis, peripheral neuropathy,
hepatic steatosis, myopathy, cardiomyopathy, pancreatitis, bone
marrow suppression, lactic acidosis, and the Fanconi syndrome.
Hepatic failure with refractory lactic acidosis is the most serious
disease complication related to mitochondrial dysfunction [22,25].
The prescribing information for all NRTIs includes a black-box
warning of the potential risk of lactic acidosis, which is constantly
updated [26]. Recently, the FDA released a new warning
regarding treatment with didanosine (ddI) about a rare, but
serious, complication: non-cirrhotic portal hypertension [27].
Stavudine [28,29] and less frequently zidovudine [30,31] have
also been previously linked to severe lactic acidosis. Although the
risk of developing lactic acidosis has fallen due to the dramatic
decrease in the number of patients receiving stavudine in the
developed world, stavudine continues to be used in developing
countries, where cases of severe toxicity continue to be seen [32].
Therefore, the NRTI-sparing strategy might be of particular
interest in resource-poor settings whereby, in addition to avoiding
the above-mentioned toxicities, more affordable strategies could
allow more efficient access to ART.
One of the possible limitations of the current study is the small
sample size and the fact that the calculated sample size was not
achieved due to low recruitment rate. However, the differences
between the two groups with respect to virologic suppression and
immunological changes were clinically non-important in addition to
not being statistically significant. This observed similarity between
the treatment groupsprovidesevidenceforthecomparabilityof their
effectiveness. Nevertheless, larger studies with longer follow up
would be helpful in confirming these conclusions. The open label
design of the study represents a methodological limitation. However,
this design is in line with real-life practice while the objective and
blinded ascertainment of virologic and immunologic parameters
precludes the possibility of differential ascertainment bias.
In conclusion, our study reports encouraging preliminary
safety and efficacy outcomes using an individualized, simplifica-
tion maintenance strategy of LPV/r monotherapy with NRTI
re-introduction upon viral rebound in plasma, among virolog-
ically suppressed patients on their first PI/r-based HAART.
Based on these results, our strategy of simplified maintenance
with LPV/r monotherapy merits further prospective long term
evaluation of its safety and effectiveness in larger cohorts.
Evaluation of the simplified strategy proposed here is particu-
larly important as it provides a potentially simple and more
affordable strategy for long term ART, that may be particularly
relevant to the current global effort to expand access to HAART
to millions in need.
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Figure 3. PROs by Treatment Group and Follow-Up Visits.
1 Dotted lines represent the linear regression function based on the least squares
method.
2 SDM, Symptoms Distress Module; &, Standard Treatment; ¤, Induction/Maintenance. * P-value for between-group difference in change over
time based on Repeated Measures Analysis of Variance
{ P-value for within-group change over time based on linear regression analysis.
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Simplified LPV/r Maintenance Strategy in HIV-1
PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e23726References
1. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the
use of antiretroviral agents in HIV-1-infected adults and adolescents Department
of Health and Human Services. December 1.(2009) pp 1–161. Available: http://
www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 2010
Mar 30.
2. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, et al. (2004)
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in
antiretroviral-naı ¨ve patients: a 3-year randomized trial. JAMA 292(2): 191–201.
3. Gulick RM, Meibohm A, Havlir D, Eron JJ, Mosley A, et al. (2003) Six-year
follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with
indinavir, zidovudine, and lamivudine. AIDS 17(16): 2345–9.
4. Hicks C, King MS, Gulick RM, White AC Jr., Eron JJ Jr., et al. (2004) Long-
term safety and durable antiretroviral activity of lopinavir/ritonavir in
treatment-naı ¨ve patients: 4 year follow-up study. AIDS 18(5): 775–9.
5. Murphy RL, da Silva BA, Hicks CB, Eron JJ, Gulick RM, et al. (2008) Seven-
year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naı ¨ve HIV-
1-infected patients. HIV Clin Trials 9(1): 1–10.
6. Bangsberg DR, Porco TC, Kagay C, Charlebois ED, Deeks SG, et al. (2004)
Modeling the HIV protease inhibitor adherence-resistance curve by use of
empirically derived estimates. J Infect Dis 190(1): 162–5.
7. Braithwaite RS, Shechter S, Roberts MS, Schaefer A, Bangsberg DR, et al.
(2006) Explaining variability in the relationship between antiretroviral adherence
and HIV mutation accumulation. J Antimicrob Chemother 58(5): 1036–43.
8. McKinnon JE, Mellors JW, Swindells S (2009) Simplification strategies to reduce
antiretroviral drug exposure: progress and prospects. Antivir Ther 14(1): 1–12.
9. Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, et al. (1998) ABT-378,
a highly potent inhibitor of the human immunodeficiency virus protease.
Antimicrob Agents Chemother 42(12): 3218–24.
10. Walmsley S, Bernstein B, King M, Arribas J, Beall G, et al. (2002) Lopinavir-
ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med
346(26): 2039–46.
11. Domingo P, Sua ´rez-Lozano I, Torres F, Teira R, Lopez-Aldeguer J, et al. (2008)
First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two
nucleoside analogues: the SUSKA study, a non-randomized comparison from
the VACH cohort. J Antimicrob Chemother 61(6): 1348–58.
12. Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, et al. (2008)
Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in
antiretroviral-naive HIV-infected patients. AIDS 22(3): 385–93.
13. Arribas JR, Delgado R, Arranz A, Mun ˜oz R, Portilla J, et al. (2009) Lopinavir-
ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for
maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr
51(2): 147–52.
14. Pulido F, Arribas JR, Delgado R, Cabrero E, Gonza ´lez-Garcı ´a J, et al. (2008)
OK04 Study Group. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir
and two nucleosides for maintenance therapy of HIV. AIDS 22(2): F1–9.
15. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA (2009)
HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic
review. AIDS Jan 28; 23(3): 279–91.
16. Pulido F, Delgado R, Pe ´rez-Valero I, Gonza ´lez-Garcı ´a J, Miralles P, et al. (2008)
Long-term (4 years) efficacy of lopinavir / ritonavir monotherapy for
maintenance of HIV suppression. J Antimicrob Chemother 61(6): 1359–61.
17. Cameron DW, da Silva BA, Arribas JR, Myers RA, Bellos NC http://www.
ncbi.nlm.nih.gov/pubmed?term=%22King MS%22%5BAuthor%5Detal, A
96-week comparison of lopinavir-ritonavir combination therapy followed by
lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect
Dis 198(2): 234–40.
18. Nunes EP, Santini de Oliveira M, Merc ¸on M, Zajdenverg R, Faulhaber JC,
et al. (2009) Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-
1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot
trial (KalMo study). HIV Clin Trials 10(6): 368–74.
19. Hall AM, Hendry BM, Nitsch D, Connolly JO (2011) Tenofovir-Associated
Kidney Toxicity in HIV-Infected Patients: A Review of the Evidence.
Am J Kidney Dis May; 57(5): 773–80.
20. Woodward CL, Hall AM, Williams IG, Madge S, Copas A, et al. (2009)
Tenofovir-associated renal and bone toxicity. HIV Med Sep; 10(8): 482–7.
21. Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, et al. (2011)
Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-
infected persons. AIDS Jun 19; 25(10): 1289–98.
22. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP (1998)
Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as
common pathway. AIDS 12: 1735–1744.
23. Kakuda TN, Brundage RC, Anderson PL, Fletcher CV (1999) Nucleoside
reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for
lipodystrophy. AIDS 13: 2311–2312.
24. Co ˆte ´ HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, et al. (2002)
Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-
infected patients. N Engl J Med 346(11): 811–20.
25. Carr A, Morey A, Mallon P, Williams D, Thorburn DR (2001) Fatal portal
hypertension, liver failure, and mitochondrial dysfunction after HIV-1
nucleoside analogue-induced hepatitis and lactic acidaemia. Lancet 357(9266):
1412–4.
26. Drug Safety Communication U.S. Food and Drug Administration, Available:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHu-
manMedicalProducts/default.htm..
27. Drug Safety Communication U.S. Food and Drug Administration, January
29, Available: http://www.fda.gov/Safety/MedWatch/SafetyInformation/
SafetyAlertsforHumanMedicalProducts/ucm199343.htm. Accessed 2010 Feb
10.
28. Mokrzycki MH, Harris C, May H, Laut J, Palmisano J (2000) Lactic acidosis
associated with stavudine administration: a report of five cases. Clin Infect Dis
30(1): 198–200.
29. Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA (2000) Lactic
acidosis and hepatic steatosis associated with use of stavudine: report of four
cases. Ann Intern Med 133(3): 192–6.
30. Stein DS (1994) A new syndrome of hepatomegaly with severe steatosis in HIV
seropositive patients. AIDS Clin Care 6: 17–21.
31. Sundar K, Suarez M, Banogon PE, Shapiro JM (1997) Zidovudine-induced fatal
lactic acidosis and hepatic failure in patients with acquired immunodeficiency
syndrome: report of two patients and review of the literature. Crit Care Med
25(8): 1425–30.
32. Hill A, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, et al. (2007)
Systematic review of clinical trials evaluating low doses of stavudine as part of
antiretroviral treatment. Expert Opin Pharmacother 8(5): 679–88.
Simplified LPV/r Maintenance Strategy in HIV-1
PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23726